These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 28369673)

  • 1. Neurological toxicities and coagulation disorders in the cytokine release syndrome during CAR-T therapy.
    Mei H; Jiang H; Wu Y; Guo T; Xia L; Jin R; Hu Y
    Br J Haematol; 2018 Jun; 181(5):689-692. PubMed ID: 28369673
    [No Abstract]   [Full Text] [Related]  

  • 2. Assessment and management of cytokine release syndrome and neurotoxicity following CD19 CAR-T cell therapy.
    Chou CK; Turtle CJ
    Expert Opin Biol Ther; 2020 Jun; 20(6):653-664. PubMed ID: 32067497
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia.
    Santomasso BD; Park JH; Salloum D; Riviere I; Flynn J; Mead E; Halton E; Wang X; Senechal B; Purdon T; Cross JR; Liu H; Vachha B; Chen X; DeAngelis LM; Li D; Bernal Y; Gonen M; Wendel HG; Sadelain M; Brentjens RJ
    Cancer Discov; 2018 Aug; 8(8):958-971. PubMed ID: 29880584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy.
    Hay KA
    Br J Haematol; 2018 Nov; 183(3):364-374. PubMed ID: 30407609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CAR T-Cell Associated Neurotoxicity: Mechanisms, Clinicopathologic Correlates, and Future Directions.
    Hunter BD; Jacobson CA
    J Natl Cancer Inst; 2019 Jul; 111(7):646-654. PubMed ID: 30753567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies.
    Freyer CW; Porter DL
    J Allergy Clin Immunol; 2020 Nov; 146(5):940-948. PubMed ID: 32771558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CAR-T cell: Toxicities issues: Mechanisms and clinical management.
    Wallet F; Sesques P; Devic P; Levrard M; Ader F; Friggeri A; Bachy E
    Bull Cancer; 2021 Oct; 108(10S):S117-S127. PubMed ID: 34920794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chimeric antigen receptor T-cell therapy in patients with neurologic comorbidities.
    Rubinstein JD; Nelson AS; Krupski C; O'Brien W; Taylor JM; Badgett TC; Huang M; Davies SM; Phillips CL
    Pediatr Blood Cancer; 2020 Apr; 67(4):e28199. PubMed ID: 32020723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy.
    Acharya UH; Dhawale T; Yun S; Jacobson CA; Chavez JC; Ramos JD; Appelbaum J; Maloney DG
    Expert Rev Hematol; 2019 Mar; 12(3):195-205. PubMed ID: 30793644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving the safety of CAR-T cell therapy by controlling CRS-related coagulopathy.
    Jiang H; Liu L; Guo T; Wu Y; Ai L; Deng J; Dong J; Mei H; Hu Y
    Ann Hematol; 2019 Jul; 98(7):1721-1732. PubMed ID: 31055613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The biological basis and clinical symptoms of CAR-T therapy-associated toxicites.
    Titov A; Petukhov A; Staliarova A; Motorin D; Bulatov E; Shuvalov O; Soond SM; Piacentini M; Melino G; Zaritskey A; Barlev NA
    Cell Death Dis; 2018 Sep; 9(9):897. PubMed ID: 30181581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic Evaluation of Neurotoxicity in Children and Young Adults Undergoing CD22 Chimeric Antigen Receptor T-Cell Therapy.
    Shalabi H; Wolters PL; Martin S; Toledo-Tamula MA; Roderick MC; Struemph K; Kane E; Yates B; Delbrook C; Mackall CL; Lee DW; Fry TJ; Shah NN
    J Immunother; 2018 Sep; 41(7):350-358. PubMed ID: 30048343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utility of a safety switch to abrogate CD19.CAR T-cell-associated neurotoxicity.
    Foster MC; Savoldo B; Lau W; Rubinos C; Grover N; Armistead P; Coghill J; Hagan RS; Morrison K; Buchanan FB; Cheng C; Laing S; Ivanova A; West J; Foster A; Serody J; Dotti G
    Blood; 2021 Jun; 137(23):3306-3309. PubMed ID: 33624095
    [No Abstract]   [Full Text] [Related]  

  • 14. A Concise Review of Neurologic Complications Associated with Chimeric Antigen Receptor T-cell Immunotherapy.
    Ruff MW; Siegler EL; Kenderian SS
    Neurol Clin; 2020 Nov; 38(4):953-963. PubMed ID: 33040871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study.
    Azoulay É; Castro P; Maamar A; Metaxa V; de Moraes AG; Voigt L; Wallet F; Klouche K; Picard M; Moreau AS; Van De Louw A; Seguin A; Mokart D; Chawla S; Leroy J; Böll B; Issa N; Levy B; Hemelaar P; Fernandez S; Munshi L; Bauer P; Schellongowski P; Joannidis M; Moreno-Gonzalez G; Galstian G; Darmon M; Valade S;
    Lancet Haematol; 2021 May; 8(5):e355-e364. PubMed ID: 33894170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytokine release syndrome associated with chimeric-antigen receptor T-cell therapy: clinicopathological insights.
    Obstfeld AE; Frey NV; Mansfield K; Lacey SF; June CH; Porter DL; Melenhorst JJ; Wasik MA
    Blood; 2017 Dec; 130(23):2569-2572. PubMed ID: 29074500
    [No Abstract]   [Full Text] [Related]  

  • 17. CAR T-cell therapy-related neurotoxicity in paediatric acute lymphocytic leukaemia.
    Tan AP
    Pediatr Blood Cancer; 2020 Nov; 67(11):e28635. PubMed ID: 32770654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of cytokine release syndrome related to CAR-T cell therapy.
    Chen H; Wang F; Zhang P; Zhang Y; Chen Y; Fan X; Cao X; Liu J; Yang Y; Wang B; Lei B; Gu L; Bai J; Wei L; Zhang R; Zhuang Q; Zhang W; Zhao W; He A
    Front Med; 2019 Oct; 13(5):610-617. PubMed ID: 31571160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toxicities of CAR T-Cell Therapy and the Role of the Consultation-Liaison Psychiatrist.
    Pawar DS; Molinaro JR; Knight JM; Heinrich TW
    Psychosomatics; 2019; 60(5):519-523. PubMed ID: 30717979
    [No Abstract]   [Full Text] [Related]  

  • 20. Chimeric Antigen Receptor Therapy in Acute Lymphoblastic Leukemia Clinical Practice.
    Luskin MR; DeAngelo DJ
    Curr Hematol Malig Rep; 2017 Aug; 12(4):370-379. PubMed ID: 28656487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.